Mountain Pacific Investment Advisers Inc. ID Sells 25 Shares of Eli Lilly and Company (NYSE:LLY)

Mountain Pacific Investment Advisers Inc. ID reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 385 shares of the company’s stock after selling 25 shares during the period. Mountain Pacific Investment Advisers Inc. ID’s holdings in Eli Lilly and Company were worth $224,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $27,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $35,000. Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $36,000. Finally, Family CFO Inc acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Truist Financial reiterated a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

LLY stock traded up $8.64 during midday trading on Friday, reaching $733.51. 2,009,249 shares of the company’s stock traded hands, compared to its average volume of 2,265,427. The company has a 50-day moving average price of $761.79 and a two-hundred day moving average price of $666.06. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 52 week low of $380.77 and a 52 week high of $800.78. The firm has a market capitalization of $696.95 billion, a PE ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.